Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for prevention of atherosclerosis in chronic kidney disease
ChiCTR1900021393Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in chronic kidney disease (CKD) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Atherosclerosis at 36 months. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR1900021393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021393.